Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386.
Article
CAS
PubMed
Google Scholar
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
CAS
PubMed
PubMed Central
Google Scholar
Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
Article
Google Scholar
Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718–30.
Article
CAS
PubMed
Google Scholar
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800.
Article
CAS
PubMed
Google Scholar
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
Article
CAS
PubMed
Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Article
CAS
PubMed
Google Scholar
Vander Heiden MG. Exploiting tumor metabolism: challenges for clinical translation. J Clin Invest. 2013;123:3648–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148:1132–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297–308.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10:671–84.
Article
CAS
PubMed
Google Scholar
Young VR, Ajami AM. Glutamine: the emperor or his clothes? J Nutr. 2001;131:2449S–59S.
CAS
PubMed
Google Scholar
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.
Article
CAS
PubMed
Google Scholar
Pingitore P, Pochini L, Scalise M, Galluccio M, Hedfalk K, Indiveri C. Large scale production of the active human ASCT2 (SLC1A5) transporter in Pichia pastoris--functional and kinetic asymmetry revealed in proteoliposomes. Biochim Biophys Acta. 2013;1828:2238–46.
Article
CAS
PubMed
Google Scholar
di Salvo ML, Contestabile R, Paiardini A, Maras B. Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection. Med Hypotheses. 2013;80:633–6.
Article
PubMed
Google Scholar
Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336:1040–4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15:157–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Diks SH, Peppelenbosch MP. Single cell proteomics for personalised medicine. Trends Mol Med. 2004;10:574–7.
Article
CAS
PubMed
Google Scholar
Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999;19:1720–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20:1981–9.
Article
CAS
PubMed
Google Scholar
Akbani R, Baker KF, Carragher N, Goldstein T, de Koning L, Korf U, et al. Realizing the promise of reverse phase protein arrays for clinical, translational and basic research: a workshop report. Mol Cell Proteomics. 2014. https://doi.org/10.1074/mcp.O113.034918
Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011;8:11.
Article
PubMed
PubMed Central
Google Scholar
Boyd ZS, Wu QJ, O’Brien C, Spoerke J, Savage H, Fielder PJ, et al. Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther. 2008;7:3695–706.
Article
CAS
PubMed
Google Scholar
Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, et al. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011;178:548–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. New York: Wiley; 2011. http://nbn-resolving.de/urn:nbn:de:101:1-201411168422, Accessed 14 Feb 2017.
Google Scholar
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.
Article
Google Scholar
Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman J-AW, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:2127–32.
Article
Google Scholar
Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, Schmidt C, et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis. 2012;1:e16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A, et al. Infrared-based protein detection arrays for quantitative proteomics. Proteomics. 2007;7:558–64.
Article
CAS
PubMed
Google Scholar
Mannsperger HA, Gade S, Henjes F, Beissbarth T, Korf U. RPPanalyzer: analysis of reverse-phase protein array data. Bioinforma Oxf Engl. 2010;26:2202–3.
Article
CAS
Google Scholar
Galili T. dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering. Bioinforma Oxf Engl. 2015;31:3718–20.
Article
CAS
Google Scholar
Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982;69:553–66.
Article
Google Scholar
Modeling Survival Data: extending the Cox Model. Terry M. Therneau. Springer. http://www.springer.com/de/book/9780387987842. Accessed 9 Dec 2016.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289–300.
Google Scholar
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–452.
Article
CAS
PubMed
Google Scholar
R Core Team. R: A Language and environment for statistical computing. 2013. https://www.r-project.org/. Accessed 12 Dec 2016.
Google Scholar
Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Myhre S, Lingjærde O-C, Hennessy BT, Aure MR, Carey MS, Alsner J, et al. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol Oncol. 2013;7:704–18.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35:427–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dolfi SC, Chan LL, Qiu J, Tedeschi PM, Bertino JR, Hirshfield KM, et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 2013;1:20.
Article
PubMed
PubMed Central
Google Scholar
Ren P, Yue M, Xiao D, Xiu R, Gan L, Liu H, et al. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol. 2015;235:90–100.
Article
CAS
PubMed
Google Scholar
Huang F, Zhao Y, Zhao J, Wu S, Jiang Y, Ma H, et al. Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. Int J Clin Exp Pathol. 2014;7:6006–14.
CAS
PubMed
PubMed Central
Google Scholar
Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol. 2015;236:278–89.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu Y, Yang L, An H, Chang Y, Zhang W, Zhu Y, et al. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. Sci Rep. 2015;5:16954.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer. 2014;110:2030–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Adeva MM, Souto G, Blanco N, Donapetry C. Ammonium metabolism in humans. Metabolism. 2012;61:1495–511.
Article
CAS
PubMed
Google Scholar
Marin M, Lavillette D, Kelly SM, Kabat D. N-linked glycosylation and sequence changes in a critical negative control region of the ASCT1 and ASCT2 neutral amino acid transporters determine their retroviral receptor functions. J Virol. 2003;77:2936–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nakaya M, Xiao Y, Zhou X, Chang J-H, Chang M, Cheng X, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity. 2014;40:692–705.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254–66.
Article
CAS
PubMed
Google Scholar
Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M, et al. Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer. 2014;135:1060–71.
Article
CAS
PubMed
Google Scholar
Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013;122:3521–32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, et al. Quantification of metabolites in patients with breast cancer with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010;23:424–31.
CAS
PubMed
Google Scholar